Search company, investor...

Predict your next investment

Venture Capital
wpssinvestments.com

Investments

9

Portfolio Exits

2

About WPSS Investments

WPSS Investments is a healthcare investor.

Headquarters Location

Want to inform investors similar to WPSS Investments about your company?

Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.

Latest WPSS Investments News

COMPASS PATHWAYS (NASDAQ:CMPS) IPO PROVES PSYCHEDELIC MEDICINE INVESTMENT THESIS

Oct 2, 2020

COMPASS PATHWAYS (NASDAQ:CMPS) IPO PROVES PSYCHEDELIC MEDICINE INVESTMENT THESIS | Source: WPSS Investments Compass Pathways IPO marks the first liquidity event for WPSS. WPSS invested in Compass Pathway’s series B alongside Founders Fund and McQuade/Otsuka. Compass Pathways IPO marks the first liquidity event for WPSS. New York City, Oct. 01, 2020 (GLOBE NEWSWIRE) -- WPSS Investments, a pioneer biotech Venture Capital fund focused on brain health and psychedelic medicine, celebrates the successful IPO of its portfolio company Compass Pathways. On September 18th, 2020 Compass Pathways was listed (NASDAQ:CMPS, ISIN:US20451W1018), making it the first psychedelic company to be listed on a U.S. exchange. CMPS´s price per share has surged more than 100% since its initial listing price of 17USD, turning it into the most valuable and first unicorn psychedelic medicine company in the world. Compass Pathways, was co-founded several years ago by George Goldsmith and Ekaterina Malievskaia who experienced the painful effects of depression within their own family. Together Lars Christian Wilde they set out to develop psilocybin (the active compound in magic mushrooms) for use in patients with treatment-resistant depression. Compass Pathways is currently in phase II trials of the FDA which should bring in promising results in 2021. WPSS invested in Compass Pathway’s series B alongside Founders Fund and McQuade/Otsuka. Compass Pathways IPO marks the first liquidity event for WPSS. In addition, WPSS has recently made other investments in revolutionary treatments and cures for neuropsychiatric disorders. These include Perception Neuroscience, a start-up that is developing r-ketamine as the safest rapid-acting antidepressant in the market, and ATAI Lifesciences, a neuropsychiatric company with the broadest portfolio of psychedelic compounds. The mental health crisis is one that has been present throughout recorded history and has intensified in past decades. One in ten people currently suffer from a psychopathology and it is estimated that between 30-50% of the world population will suffer from a mental illness at some point in their life. The isolation, loss and uncertainty felt during the COVID-19 crisis has served to further highlight the magnitude and importance of this parallel, silent epidemic. It is estimated that severe mental illness shortens life span by 10 -25 years The yearly global direct and indirect cost of these diseases is estimated to be $2.5 trillion. Although neuropsychiatric disorders are both widespread and costly, treatments available are scarce and highly ineffectual. For example, about 30% of depression patients do not respond to any currently available treatment. New treatments are desperately needed and psychedelics are paving the way to a new era of mental health. Sonia Weiss Pick, Co-Founder at WPSS Investments, says “Psychedelics have been used by humans as tools for healing for millennia. Ample clinical trials have shown that these compounds are both safe and non-addictive if used correctly. Additional studies are being conducted to establish its full therapeutic potential and the mechanisms by which they act on the body. I am convinced that psychedelic medicine will forever change our understanding of brain health.” About WPSS Investments  WPSS Investments is a Venture Capital fund focused on finding the most revolutionary diagnostics, treatments and cures for neuropsychiatric disorders. Founded and led by an entrepreneurial investment team, WPSS provides funds early stage companies led by business savvy scientists and engineers with a drive to change the world. WPSS’ Investments span psychedelic medicine, non-invasive devices, novel biomarkers and diagnostics, amongst others.

WPSS Investments Investments

9 Investments

WPSS Investments has made 9 investments. Their latest investment was in Alto Neuroscience as part of their Series A on October 10, 2021.

CBI Logo

WPSS Investments Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

10/14/2021

Series A

Alto Neuroscience

$32M

Yes

9

9/27/2021

Series A

Subscribe to see more

$99M

Subscribe to see more

10

3/3/2021

Series D

Subscribe to see more

$99M

Subscribe to see more

10

11/23/2020

Series C

Subscribe to see more

$99M

Subscribe to see more

10

7/30/2020

Convertible Note - IV

Subscribe to see more

$99M

Subscribe to see more

10

Date

10/14/2021

9/27/2021

3/3/2021

11/23/2020

7/30/2020

Round

Series A

Series A

Series D

Series C

Convertible Note - IV

Company

Alto Neuroscience

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Amount

$32M

$99M

$99M

$99M

$99M

New?

Yes

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Co-Investors

Sources

9

10

10

10

10

WPSS Investments Portfolio Exits

2 Portfolio Exits

WPSS Investments has 2 portfolio exits. Their latest portfolio exit was ATAI Life Sciences on June 18, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

6/18/2021

IPO

$99M

Public

17

9/18/2020

IPO

Subscribe to see more

$99M

Subscribe to see more

10

Date

6/18/2021

9/18/2020

Exit

IPO

IPO

Companies

Subscribe to see more

Valuation

$99M

$99M

Acquirer

Public

Subscribe to see more

Sources

17

10

WPSS Investments Acquisitions

1 Acquisition

WPSS Investments acquired 1 company. Their latest acquisition was Perception Neuroscience on January 03, 2019.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

1/3/2019

$99M

Corporate Majority

2

Date

1/3/2019

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Corporate Majority

Sources

2

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.